Advertisement
UK markets open in 6 hours 6 minutes
  • NIKKEI 225

    38,291.02
    +88.65 (+0.23%)
     
  • HANG SENG

    18,313.86
    -165.51 (-0.90%)
     
  • CRUDE OIL

    79.28
    +0.29 (+0.37%)
     
  • GOLD FUTURES

    2,315.90
    -6.40 (-0.28%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • Bitcoin GBP

    49,134.95
    -1,000.65 (-2.00%)
     
  • CMC Crypto 200

    1,306.64
    +11.97 (+0.92%)
     
  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     
  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     

GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment

GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment

To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators, Anoro and Incruse. The company also expects to see COPD patients who are at higher risk of exacerbations to shift from open triple therapy to closed triple therapy such as the recently launched Trelegy Ellipta.